nach oben

Advances in Therapy

Erschienen in:

01.07.2013 | Review

Targeting the Gut–Liver Axis in Cirrhosis: Antibiotics and Non-Selective β-Blockers

verfasst von: Bjørn S. Madsen, Troels Havelund, Aleksander Krag

Erschienen in: Advances in Therapy | Ausgabe 7/2013

Einloggen, um Zugang zu erhalten

Abstract

The gut–liver axis in cirrhosis and portal hypertension is gaining increasing attention as a key pathophysiological mechanism responsible for progression of liver failure and development of complications such as spontaneous infections and hepatocellular carcinoma. Antibiotics and non-selective β-blockers (NSBB) intercept this axis and each drug has proven efficacy in clinical trials. A synergistic effect is a hitherto unproven possibility. There is an increasing body of evidence supporting improved outcome with expanded use of NSBB and antibiotic therapy beyond current indications. This review addresses the issue of pharmacological treatment of cirrhosis and portal hypertension with antibiotics and NSBB. We discuss their mechanism of action and suggest that combining the two treatment modalities could potentially reduce the risk of complications.

Schuppan D, Afdhal NH. Liver cirrhosis. Lancet. 2008;371:838–51.PubMedCrossRef

D’Amico G, Garcia-Tsao G, Pagliaro L. Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies. J Hepatol. 2006;44:217–31.PubMedCrossRef

Nolan JP. The role of intestinal endotoxin in liver injury: a long and evolving history. Hepatology. 2010;52:1829–35.PubMedCrossRef

Worlicek M, Knebel K, Linde HJ, et al. Splanchnic sympathectomy prevents translocation and spreading of E coli but not S aureus in liver cirrhosis. Gut. 2010;59:1127–34.PubMedCrossRef

Xu WH, Wu XJ, Li JS. Influence of portal pressure changes on intestinal permeability in patients with portal hypertension. Hepatobiliary Pancreat Dis Int. 2002;1:510–4.PubMed

Chesta J, Defilippi CL, Defilippi C. Abnormalities in proximal small bowel motility in patients with cirrhosis. Hepatology. 1993;17:828–32.PubMed

Lorenzo-Zúñiga V, Bartolí R, Planas R, et al. Oral bile acids reduce bacterial overgrowth, bacterial translocation, and endotoxemia in cirrhotic rats. Hepatology. 2003;37:551–7.PubMedCrossRef

Yang L, Seki E. Toll-like receptors in liver fibrosis: cellular crosstalk and mechanisms. Front Physiol. 2012;3:138.PubMed

Seo YS, Shah VH. The role of gut-liver axis in the pathogenesis of liver cirrhosis and portal hypertension. Clin Mol Hepatol. 2012;18:337–46.PubMedCrossRef

10.

Szabo G, Bala S, Petrasek J, Gattu A. Gut-liver axis and sensing microbes. Dig Dis. 2010;28:737–44.PubMedCrossRef

11.

Senzolo M, Cholongitas E, Burra P, et al. Beta-blockers protect against spontaneous bacterial peritonitis in cirrhotic patients: a meta-analysis. Liver Int. 2009;29:1189–93.PubMedCrossRef

12.

Perez-Paramo M, Munoz J, Albillos A, et al. Effect of propranolol on the factors promoting bacterial translocation in cirrhotic rats with ascites. Hepatology. 2000;31:43–8.PubMedCrossRef

13.

Cirera I, Bauer TM, Navasa M, et al. Bacterial translocation of enteric organisms in patients with cirrhosis. J Hepatol. 2001;34:32–7.PubMedCrossRef

14.

Gines P, Rimola A, Planas R, et al. Norfloxacin prevents spontaneous bacterial peritonitis recurrence in cirrhosis: results of a double-blind, placebo-controlled trial. Hepatology. 1990;12:716–24.PubMedCrossRef

15.

Wiest R, Garcia-Tsao G. Bacterial translocation (BT) in cirrhosis. Hepatology. 2005;41:422–33.PubMedCrossRef

16.

Chang CS, Chen GH, Lien HC, Yeh HZ. Small intestine dysmotility and bacterial overgrowth in cirrhotic patients with spontaneous bacterial peritonitis. Hepatology. 1998;28:1187–90.PubMedCrossRef

17.

Morencos FC, de la Heras Castano G, Martin Ramos L, Lopez Arias MJ, Ledesma F, Pons Romero F. Small bowel bacterial overgrowth in patients with alcoholic cirrhosis. Dig Dis Sci. 1995;40:1252–6.PubMedCrossRef

18.

Floch MH. Bile salts, intestinal microflora and enterohepatic circulation. Digest Liver Dis. 2002;34:54–7.CrossRef

19.

Bauer TM, Steinbrukner B, Brinkmann FE, et al. Small intestinal bacterial overgrowth in patients with cirrhosis; prevalence and relation with spontaneous bacterial peritonitis. Am J Gastroenterol. 2001;96:2962–7.PubMedCrossRef

20.

Koh IH, Guatelli R, Montero EF, et al. Where is the site of bacterial translocation: small or large bowel? Transpl Proc. 1996;28:2661.

21.

Chen Y, Yang F, Lu H, et al. Characterization of fecal microbial communities in patients with liver cirrhosis. Hepatology. 2011;54:562–72.PubMedCrossRef

22.

Alverdy J, Holbrook C, Rocha F, et al. Gut-derived sepsis occurs when the right pathogen with the right virulence genes meets the right host: evidence for in vivo virulence expression in Pseudomonas aeruginosa. Ann Surg. 2000;232:480–9.PubMedCrossRef

23.

Steffen EK, Berg RD. Relationship between cecal population levels of indigenous bacteria and translocation to mesenteric lymph nodes. Infect Immun. 1983;39:1252–9.PubMed

24.

Jun DW, Kim KT, Lee OY, et al. Association between small intestinal overgrowth and peripheral bacterial DNA in cirrhotic patients. Dig Dis Sci. 2010;55:1465–71.PubMedCrossRef

25.

Guarner C, Runyon BA, Young S, Heck M, Sheik MY. Intestinal bacterial overgrowth and bacterial translocation in cirrhotic rats with ascites. J Hepatol. 1997;26:1372–8.PubMedCrossRef

26.

Simonovic I, Rosenberg J, Koutsouris A, Hecht G. Enteropathogenic Escherichia coli dephosphorylates and dissociates occluding from intestinal epithelial tight junctions. Cell Microbiol. 2000;2:305–15.PubMedCrossRef

27.

Assimakopoulos SF, Tsamandas AC, Tsiaoussis GI, et al. Altered intestinal tight junctions’ expression in patients with liver cirrhosis: a pathogenetic mechanism of intestinal hyperpermeability. Eur J Clin Invest. 2012;42:439–46.PubMedCrossRef

28.

Scarpellini E, Valenza A, Gabrielli M, et al. Intestinal permeability in cirrhotic patients with and without spontaneous bacterial peritonitis: is the ring closed? Am J Gastroenterol. 2010;105:323–7.PubMedCrossRef

29.

Hollander D. Intestinal permeability, leaky gut, and intestinal disorders. Curr Gastroenterol Rep. 1999;1:410–6.PubMedCrossRef

30.

Fouts DE, Torralba M, Nelson KE, Brenner DA, Schnabl B. Bacterial translocation and changes in the intestinal microbiome in mouse models of liver disease. J Hepatol. 2012;56:1283–92.PubMedCrossRef

31.

Ruiz-del-Arbol, Urman J, Fernández J, et al. Systemic, renal, and hepatic hemodynamic derangement in cirrhotic patients with spontaneous bacterial peritonitis. Hepatology. 2003;38:1210–8.PubMedCrossRef

32.

Jalan R, Gines P, Olson JC, et al. Acute-on chronic liver failure. J Hepatol. 2012;57:1336–48.PubMedCrossRef

33.

Hou MC, Lin HC, Liu TT, et al. Antibiotic prophylaxis after endoscopic therapy prevents rebleeding in acute variceal hemorrhage: a randomized trial. Hepatology. 2004;39:746–53.PubMedCrossRef

34.

Wong F, Bernardi M, Balk R, et al. Sepsis in cirrhosis: report of the 7th meeting of the International Ascites Club. Gut. 2005;54:718–25.PubMedCrossRef

35.

Lin RS, Lee FY, Lee SD, et al. Endotoxemia in patients with chronic liver disease: relationship to severity of liver diseases, presence of esophageal varices, and hyperdynamic circulation. J Hepatol. 1995;22:165–72.PubMedCrossRef

36.

Zapater P, Francés R, González-Navajas JM, et al. Serum and ascites fluid bacterial DNA: a new independent prognostic factor in noninfected patients with cirrhosis. Hepatology. 2008;48:1924–31.PubMedCrossRef

37.

Albillos A, de la Hera A, González M, et al. Increased lipopolysaccharide binding protein in cirrhotic patients with marked immune and hemodynamic derangement. Hepatology. 2003;37:208–17.PubMedCrossRef

38.

Bellot P, Francés R, Such J. Pathological bacterial translocation in cirrhosis: pathophysiology, diagnosis and clinical implications. Liver Int. 2013;33:31–9.PubMedCrossRef

39.

Seki E, De MS, Osterreicher CH, et al. TLR4 enhances TGF-beta signaling and hepatic fibrosis. Nat Med. 2007;13:1324–32.PubMedCrossRef

40.

Dapito DH, Mencin A, Gwak GY, et al. Promotion of hepatocellular carcinoma by intestinal microbiota and TLR4. Cancer Cell. 2012;21:504–16.PubMedCrossRef

41.

Bajaj JS, O’Leary JG, Reddy KR, et al. Second infections independently increase mortality in hospitalized patients with cirrhosis: The North American consortium for the study of end-stage liver disease (NACSELD) experience. Hepatology. 2012;56:2328–35.PubMedCrossRef

42.

Muñoz L, Jose BM, Ubeda M, et al. Interaction between Intestinal dendritic cells and bacteria translocated from the gut in rats with cirrhosis. Hepatology. 2012;56:1861–9.PubMedCrossRef

43.

Cohen MJ, Sahar T, Benenson S, Elinav E, Brezis M, Soares-Weiser K. Antibiotic prophylaxis for spontaneous bacterial peritonitis in cirrhotic patients with ascites, without gastro-intestinal bleeding. Cochrane Database Syst Rev. 2009;CD004791.

44.

Chavez-Tapia NC, Barrientos-Gutierrez T, Tellez-Avila FL, Soares-Weiser K, Uribe M. Antibiotic prophylaxis for cirrhotic patients with upper gastrointestinal bleeding. Cochrane Database Syst Rev. 2010;CD002907.

45.

European Association for the Study of the Liver. EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis. J Hepatol. 2010;53:397–417.CrossRef

46.

Rasaratnam B, Kaye D, Jennings G, Dudley F, Chin-Dusting J. The effects of selective intestinal decontamination on the hyperdynamic circulatory state in cirrhosis. Ann Intern Med. 2003;139:186–93.PubMedCrossRef

47.

Vlachogiannakos J, Saveriadis AS, Viazis N, et al. Intestinal decontamination improves liver haemodynamics in patients with alcohol-related decompensated cirrhosis. Aliment Pharmacol Ther. 2009;29:992–9.PubMedCrossRef

48.

Wiest R, Cadelina G, Milstien S, McCuskey RS, Garcia-Tsao G, Groszmann RJ. Bacterial translocation up-regulates GTP-cyclohydrolase 1 in mesenteric vasculature of cirrhotic rats. Hepatology. 2003;38:1508–15.PubMed

49.

Kalambokis GN, Mouzaki A, Rodi M, et al. Rifaximin improves systemic hemodynamics and renal function in patients with alcohol-related cirrhosis and ascites. Clin Gastroenterol Hepatol. 2012;10:815–8.PubMedCrossRef

50.

Kemp W, Colman J, Thompson K, et al. Norfloxacin treatment for clinically significant portal hypertension: results of a randomised double-blind placebo-controlled crossover trial. Liver Int. 2009;29:427–33.PubMedCrossRef

51.

Chin-Dusting J, Rasaratnam B, Jennings GLR, Dudley FJ. Effect of fluoroquinolone on the enhanced nitric oxide-induced peripheral vasodilation seen in cirrhosis. Ann Intern Med. 1997;127:985–8.PubMedCrossRef

52.

Baveja R, Keller S, Yokoyama Y, Sonin N, Clemens MG, Zhang JX. LPS-induced imbalanced expression of hepatic vascular stress genes in cirrhosis: possible mechanism of increased susceptibility to endotoxemia. Shock. 2002;17:316–21.PubMedCrossRef

53.

Bellot P, García-Pagán JC, Francés R, et al. Bacterial DNA translocation is associated with systemic circulatory abnormalities and intrahepatic endothelial dysfunction in patients with cirrhosis. Hepatology. 2010;52:2044–52.PubMedCrossRef

54.

Kalambokis GN, Tsianos EV. Rifaximin reduces endotoxemia and improves liver function and disease severity in patients with decompensated cirrhosis. Hepatology. 2012;55:655–6.PubMedCrossRef

55.

Madrid AM, Hurtado C, Venegas M, Cumsille F, Defilipi C. Long-term treatment with cisapride and antibiotics in liver cirrhosis: effect on small intestinal motility, bacterial overgrowth, and liver function. Am J Gastroenterol. 2001;96:1251–5.PubMedCrossRef

56.

Fernandez J, Navasa M, Planas R, et al. Primary prophylaxis of spontaneous bacterial peritonitis delays hepatorenal syndrome and improves survival in cirrhosis. Gastroenterology. 2007;133:818–24.PubMedCrossRef

57.

Bass NM, Mullen KD, Sanyal A, et al. Rifaximin treatment in hepatic encephalopathy. N Engl J Med. 2010;362:1071–81.PubMedCrossRef

58.

Vlachogiannakos J, Viazis N, Vasianopoulou P, Vafiadis I, Karamanolis DG, Ladas SD. Long-term administration of rifaximin improves the prognosis of patients with decompensated alcoholic cirrhosis. J Gastroenterol Hepatol. 2013;28:450–5.PubMedCrossRef

59.

Straub RH, Wiest R, Strauch UG, Härle P, Schölmerich J. The role of the sympathetic nervous system in intestinal inflammation. Gut. 2006;55:1640–9.PubMedCrossRef

60.

Henriksen JH, Møller S, Ring-Larsen H, Christensen NJ. The sympathetic nervous system in liver disease. J Hepatol. 1998;29:328–41.PubMedCrossRef

61.

Freestone PPE, Sandrini SM, Haigh R, Lyte M. Microbial endocrinology: how stress influences susceptibility to infections. Trends Microbiol. 2008;16:55–64.PubMedCrossRef

62.

Freestone PP, Williams PH, Haigh RD, Maggs AF, Neal CP, Lyte M. Growth stimulation of intestinal commensal Escherichia coli by catecholamines: a possible contributory factor in trauma-induced sepsis. Shock. 2002;18:465–70.PubMedCrossRef

63.

McIntyre AS, Thompson DG, Day S, Burnham WR, Walker ER. Modulation of human upper intestinal nutrient transit by a beta adrenoreceptor mediated pathway. Gut. 1992;33:1062–70.PubMedCrossRef

64.

Ahluwalia NK, Thompson DG, Barlow J, Heggie L. Beta adrenergic modulation of human upper intestinal propulsive forces. Gut. 1994;35:1356–9.PubMedCrossRef

65.

Rice PA, Boehm GW, Moynihan JA, Bellinger DL, Stevens SY. Chemical sympathectomy increases numbers of inflammatory cells in the peritoneum early in murine listeriosis. Brain Behav Immun. 2002;16:654–62.PubMedCrossRef

66.

García JJ, del Carmen Sáez M, De la Fuente M, Ortega E. Regulation of phagocytic process of macrophages by noradrenaline and its end metabolite 4-hydroxy-3-metoxyphenyl-glycol. Role of alpha- and beta-adrenoreceptors. Mol Cell Biochem. 2003;254:299–304.PubMedCrossRef

67.

Shilov JI, Orlova EG. Role of adrenergic mechanisms in regulation of phagocytic cell functions in acute stress response. Immunol Lett. 2003;86:229–33.PubMedCrossRef

68.

Garcia-Tsao G, Bosch J. Management of varices and variceal hemorrhage in cirrhosis. N Engl J Med. 2010;362:823–32.PubMedCrossRef

69.

Thiele M, Krag A, Rohde U, Gluud LL. Meta-analysis: banding ligation and medical interventions for the prevention of rebleeding from oesophageal varices. Aliment Pharmacol Ther. 2012;35:1155–65.PubMedCrossRef

70.

Senzolo M, Fries W, Buda A, et al. Oral propranolol decreases intestinal permeability in patients with cirrhosis: another protective mechanism against bleeding? Am J Gastroenterol. 2009;104:3115–6.PubMedCrossRef

71.

Villanueva C, López-Balaguer JM, Aracil C, et al. Maintenance of hemodynamic response to the treatment for portal hypertension and influence on complications of cirrhosis. J Hepatol. 2004;40:757–65.PubMedCrossRef

72.

Abraldes JG, Tarantino I, Turner J, et al. Hemodynamic response to pharmacological treatment of portal hypertension and long-term prognosis of cirrhosis. Hepatology. 2003;37:902–8.PubMedCrossRef

73.

Turnes J, Garcia-Pagan JC, Abraldes JG, Hernandez-Guerra M, Dell′Era A, Bosch J. Pharmacological reduction of portal pressure and long-term risk of first variceal bleeding in patients with cirrhosis. Am J Gastroenterol. 2006;101:506–12.PubMedCrossRef

74.

Hernández-Ghea V, Aracil C, Colomo A, et al. Development of ascites in compensated cirrhosis with severe portal hypertension treated with β-blockers. Am J Gastroenterol. 2012;107:418–27.CrossRef

75.

Nkontchou G, Aout M, Mahmoudi A, et al. Effect of long-term propranolol treatment on hepatocellular carcinoma incidence in patients with HCV-associated cirrhosis. Cancer Prev Res. 2012;5:1007–14.CrossRef

76.

Kassahun WT, Guenl B, Ungemach FR, Jonas S, Abraham G. Expression and functional coupling of liver β2-adrenoceptors in the human hepatocellular carcinoma. Pharmacology. 2012;89:313–20.PubMedCrossRef

77.

Liu X, Wu WK, Yu L, et al. Epinephrine stimulates esophageal squamous-cell carcinoma cell proliferation via beta-adrenoceptor-dependent transactivation of extracellular signal-regulated kinase/cyclooxygenase-2 pathway. J Cell Biochem. 2008;105:53–60.PubMedCrossRef

78.

Palm D, Lang K, Niggemann B, et al. The norepinephrine-driven metastasis development of PC-3 human prostate cancer cells in BALB/c nude mice is inhibited by beta-blockers. Int J Cancer. 2006;118:2744–9.PubMedCrossRef

79.

Annabi B, Lachambre MP, Pouffe K, Moumdjian R, Béliveau R. Propranolol adrenergic blockade inhibits human brain endothelial cells tubulogenesis and matrix metalloproteinase-9 secretion. Pharm Res. 2009;60:438–45.CrossRef

80.

Garcia-Tsao G, Friedman S, Iredale J, Pinzani. Now there are many (stages) where before there was one: In search of a pathophysiological classification of cirrhosis. Hepatology. 2010;51:1445–9.PubMedCrossRef

81.

Arvaniti V, D’Amico G, Fede G, et al. Infections in patients with cirrhosis increase mortality four-fold and should be used in determining prognosis. Gastroenterology. 2010;139:1246–56.PubMedCrossRef

82.

Tsochatzis EA, Bosch J, Burroughs AK. New therapeutic paradigm for patients with cirrhosis. Hepatology. 2012;56:1983–92.PubMedCrossRef

83.

Chelarescu O, Chelarescu D, Ticoveanu E, Stratan I. Propranolol administration on post surgical infections in cirrhotic patients. J Hepatol. 2003;38:A173.

84.

Sersté T, Melot C, Francoz C, et al. Deleterious effects of beta-blockers on survival in patients with cirrhosis and refractory ascites. Hepatology. 2010;52:1017–22.PubMedCrossRef

85.

Krag A, Bendtsen F, Henriksen JH, Møller S. Low cardiac output predicts development of hepatorenal syndrome and survival in patients with cirrhosis and ascites. Gut. 2010;59:105–10.PubMedCrossRef

86.

Krag A, Bendtsen F, Møller S. Does cardiac dysfunction explain deleterious effects of beta-blockers in cirrhosis and refractory ascites? Hepatology. 2011;53:370–1.PubMedCrossRef

87.

Krag A, Wiest R, Albillos A, Gluud LL. The window hypothesis: haemodynamic and non-haemodynamic effects of β-blockers improve survival of patients with cirrhosis during a window in the disease. Gut. 2012;61:967–9.PubMedCrossRef

88.

Groszmann RJ, Garcia-Tsao G, Bosch J, et al. Beta-blockers to prevent gastroesophageal varices in patients with cirrhosis. N Engl J Med. 2005;353:2254–61.PubMedCrossRef

89.

Fundació Institut de Recerca de l’Hospital de la Santa Creu i Sant Pau.Study on B-blockers to prevent decompensation of cirrhosis with HTPortal (PREDESCI). http://clinicaltrials.gov/show/NCT01059396. Study NCT01059396. Accessed March 15, 2013.

90.

Fernández J, Navasa M, Gómez J, et al. Bacterial infections in cirrhosis: epidemiological changes with invasive procedures and norfloxacin prophylaxis. Hepatology. 2002;35:140–8.PubMedCrossRef

91.

Aparicio JR, Such J, Pascual S, et al. Development of quinolone-resistant strains of Escherichia coli in stools of patients with cirrhosis undergoing norfloxacin prophylaxis: clinical consequences. J Hepatol. 1999;31:277–83.PubMedCrossRef

92.

Gerard L, Garey KW, DuPont HL. Rifaximin: a nonabsorbable rifamycin antibiotic for use in nonsystemic gastrointestinal infections. Expert Rev Anti Infect Ther. 2005;3:201–11.PubMedCrossRef

93.

Zapater P, Caño R, Llanos L, et al. Norfloxacin modulates the inflammatory response and directly affects neutrophils in patients with decompensated cirrhosis. Gastroenterology. 2009;137:1669–79.PubMedCrossRef

94.

Dalhoff A. Immunomodulatory activities of fluoroquinolones. Infection. 2005;33(Suppl. 2):55–70.PubMedCrossRef

95.

Chassaing B, Etienne-Mesmin L, Gewirtz AT. Microbiota-liver axis in hepatic disease. Hepatology. 2013; [Epub ahead of print].

96.

Zhang S, Wang W, Ren W, Dai Q, He B, Zhou K. Effects of lactulose on intestinal endotoxin and bacterial translocation in cirrhotic rats. Chin Med J. 2003;116:767–71.PubMed

97.

Sharma BC, Sharma P, Agrawal A, Sarin SK. Secondary prophylaxis of hepatic encephalopathy: an open-label randomized controlled trial on lactulose versus placebo. Gastroenterology. 2009;137:885–91.PubMedCrossRef

98.

Imani Fooladi AA, Mahmoodzadeh HH, Nourani MR, Khani S, Alavian SM. Probiotic as a novel treatment strategy against liver disease. HepatMon. 2013;13(2):e7521. doi:105812/hepatmon.7521.CrossRef

99.

Van Nood E, Vrieze A, Nieuwdorp M, et al. Duodenal infusion of donor feces for recurrent Clostridium difficile. N Engl J Med. 2013;368:407–15.PubMedCrossRef

100.

Vrieze A, Van Nood E, Holleman F, et al. Transfer of intestinal microbiota from lean donors increases insulin sensitivity in individuals with metabolic syndrome. Gastroenterology. 2012;143:913–6.PubMedCrossRef

101.

Le Roy T, Llopis M, Lepage P, et al. Intestinal microbiota determines development of non-alcoholic fatty liver disease in mice. Gut. 2012. doi:101136/gutjnl-2012-303816

102.

Blachier M, Leleu H, Peck-Radosavljevic M, Valla DC, Roudot-Thoraval F. The burden of liver disease in Europe: a review of available epidemiological data. J Hepatol. 2013;58:593–608.PubMedCrossRef

Titel: Targeting the Gut–Liver Axis in Cirrhosis: Antibiotics and Non-Selective β-Blockers
verfasst von: Bjørn S. Madsen
Troels Havelund
Aleksander Krag
Publikationsdatum: 01.07.2013
Verlag: Springer Healthcare
Erschienen in: Advances in Therapy / Ausgabe 7/2013
Print ISSN: 0741-238X
Elektronische ISSN: 1865-8652
DOI: https://doi.org/10.1007/s12325-013-0044-1

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Echinokokkose medikamentös behandeln oder operieren?

06.05.2024 DCK 2024 Kongressbericht

Die Therapie von Echinokokkosen sollte immer in spezialisierten Zentren erfolgen. Eine symptomlose Echinokokkose kann – egal ob von Hunde- oder Fuchsbandwurm ausgelöst – konservativ erfolgen. Wenn eine Op. nötig ist, kann es sinnvoll sein, vorher Zysten zu leeren und zu desinfizieren.

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Proximale Humerusfraktur: Auch 100-Jährige operieren?

01.05.2024 DCK 2024 Kongressbericht

Mit dem demographischen Wandel versorgt auch die Chirurgie immer mehr betagte Menschen. Von Entwicklungen wie Fast-Track können auch ältere Menschen profitieren und bei proximaler Humerusfraktur können selbst manche 100-Jährige noch sicher operiert werden.

Die „Zehn Gebote“ des Endokarditis-Managements

30.04.2024 Endokarditis Leitlinie kompakt

Worauf kommt es beim Management von Personen mit infektiöser Endokarditis an? Eine Kardiologin und ein Kardiologe fassen die zehn wichtigsten Punkte der neuen ESC-Leitlinie zusammen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 7/2013

Use of Pertuzumab for the Treatment of HER2-Positive Metastatic Breast Cancer

The Effect of Personality Dimensions on Functional Outcomes in Mood Disorders

C-QUALITY: Cost and Quality-of-Life Pharmacoeconomic Analysis of Antidepressants in Major Depressive Disorder in Italy